CVS Health Co. NYSE: CVStransformed from one of the largest drug store pharmacy chains in the country to an integrated healthcare company when it acquired Aetna Health Insurance for $70 billion on November 28, 2018. The plan was to offer the full gamut of healthcare services and products and grow its Minute Clinics around the country, cashing in on primary care services.
CVS Health is exiting its core infusion services business and plans to either close or sell 29 related regional pharmacies in the coming months, a company spokesperson confirmed to Reuters on Friday.
CVS Health (CVS) reachead $66.85 at the closing of the latest trading day, reflecting a +1.33% change compared to its last close.
CVS Health (CVS) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Major changes could soon be coming, but will they drive the stock up?
The stock could be poised for a turnaround.
On October 4, 2024, TD Cowen upgraded CVS Health (NYSE: CVS) to Buy from Hold, raising its price target to $85 from $59. This represents a potential upside of 35%, driven by significant updates to CVS's Medicare Advantage (MA) business.
We also chat about Uber and its quest to become an everything app.
Shares of CVS Health Corp (NYSE:CVS) are 3.9% higher to trade at $65.40 at last glance, after several updates for the healthcare giant.
Changes in in the retail pharmacy's 2025 Medicare Advantage plan benefits should lower costs.
CVS has engaged advisors in a strategic review of its business, CNBC has reported Monday. One option being weighed is splitting up its retail pharmacy and insurance units.